Skip to contentO
Oncotelic Therapeutics, Inc.
O
OTLCOncotelic Therapeutics, Inc. Q3 2025 · 10-Q
Revenue—
Net Income-$1.05M-$1.05MN/M vs Q3 2024 EPS, diluted—
Operating Income-$490,973N/M Operating Cash Flowderived-$307,022N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oncotelic Therapeutics, Inc. · CIK 908259 · Engraved from SEC EDGAR
ended Sep 30, 2025 · filed Nov 17, 2025 · 48 d after period end